Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

forts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor StatementThis press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX1031, LX1032, LX1033, LX2931, and LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. I
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon to Present at Two Major Healthcare Investor Conferences
4. Lexicon Announces Pricing of Common Stock in Public Offering
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... The Academy of Model Aeronautics Foundation would ... Model Aviation Day. The third annual celebration will be August ... the model aviation hobby nation-wide and to introduce model flying ... 2,350 chartered clubs to celebrate the hobby and share it ... There will also be a local event at the AMA ...
(Date:5/27/2015)... May 27, 2015 The ALS ... via its wholly owned subsidiary, Anelixis Therapeutics , ... for ALS that targets the innate immune system. The ... Development Institute received from the 2014 social media phenomenon ... sum of $4 million raised directly by the Institute ...
(Date:5/27/2015)... , May 27, 2015  Two years after its ... hackers and citizen scientists, Oakland -based ... campaign promoting its mission to democratize science through a ... Photo ... Based out of the new ...
(Date:5/27/2015)... 27, 2015 The Medical Innovation Impact ... of regulation on medical innovation, has been developed at ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute ... pertains to new FDA (Food & Drug Administration) ... the approval of certain medical devices. , “The ...
Breaking Biology Technology:Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 2Academy of Model Aeronautics Foundation to host National Model Aviation Day Motorcycle Rally and Family Fest in Muncie, IN 3Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 2Ice Bucket Challenge Advances Antibody Toward Clinical Trial for ALS 3East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3Medical Innovation Impact Index Launched at Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) under the Rothman Institute 2
... how to make an exact cut on a metal rod. But ... carbon nanotube, with a diameter 1/50,000th the thickness of a human ... journal Proceedings of the Royal Society A , researchers at ... single-walled carbon nanotubes are cut, a finding that could lead to ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... previously announced public offering of 25,000,000 common shares of ... US $37,650,000. In connection with the offering, the Company ... up to 3,750,000 additional common shares to cover over-allotments, ...
... Dec. 17, 2010 InterMune, Inc. (Nasdaq: ... team to prepare for the commercialization of Esbriet™ (pirfenidone) ... received a positive CHMP opinion that is now awaiting ... Chairman, Chief Executive Officer and President of InterMune, said, ...
Cached Biology Technology:How do you cut a nanotube? Lots of compression 2YM BioSciences Closes Public Offering of Common Shares 2YM BioSciences Closes Public Offering of Common Shares 3InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 2InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 3InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 4InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 5InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe 6
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/21/2015)... Canada , April 21, 2015 ... and evolving government policies are boosting access control systems ... According to a recently published report by ... Opportunities, 2020 ", the access control systems market in ... nearly USD1.2 billion by 2020.The access control systems market ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 18.3.2013 In the fruit fly Drosophila , the functions ... intertwined - among other things they are involved in neurotransmitter ... of Biochemistry showed for the first time that flies cannot ... also raises new questions as to its function. Anna Ziegler, ...
... 18, 2013 Labrys Biologics Inc., a company focused on ... lead the development of RN-307, a Phase 2 ready anti-CGRP ... M.D., Ph.D., joins Labrys as chief medical officer, along with ... of project management; Michele Bronson , Ph.D., ...
... Researchers at Albert Einstein College of Medicine of Yeshiva ... found that macrophages white blood cells that play a key ... and eliminate the body,s red blood cells (RBCs). The findings could ... red blood cell production is thrown out of balance. The study, ...
Cached Biology News:Blind flies without recycling 2Blind flies without recycling 3Labrys Biologics Announces Key Executive Appointments 2Labrys Biologics Announces Key Executive Appointments 3Labrys Biologics Announces Key Executive Appointments 4White blood cells found to play key role in controlling red blood cell levels 2White blood cells found to play key role in controlling red blood cell levels 3
...
... BD PhosFlow Perm/Wash Buffer I can be ... signaling proteins to permeabilize cells and to ... wash buffer. Because saponin-mediated cell permeabilization is ... keep the cells in the presence of ...
... Mouse polyclonal antibody raised against ... Immunogen: PPP4C ... a.a) partial recombinant protein with ... Accession Number: NM_002720 ...
... Thermomixer R offers maximum application versatility ... heating, and cooling. Its active heating/cooling ... and temperature control ranges. Five different ... micro test tubes, are available for: ...
Biology Products: